Home R&D/Publications>
Latest News
See all news



Generation of anti-IL-17B antibodies neutralizing IL-17B-mediated alterations of the immune microenvironment, promotion of tumor cell initiating capacity and chemoresistance

Emilie Laprevotte, Aurélie Docquier, Jérémy Bastid, Cécile Déjou, Marion Lapierre, Gilles Alberici, Armand Bensussan, Jean-François Eliaou, Nathalie Bonnefoy, AACR Annual Meeting 2017, Washington DC, April 2017.

IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells

Merrouche Y, Fabre J, Cure H, Garbar C, Fuselier C, Bastid J, Antonicelli F, Al-Daccak R, Bensussan A, Giustiniani J, Oncotarget, 2016 Aug 16.

Targeting the Tumor Microenvironment: The Protumor Effects of IL-17 Related to Cancer Type

Joseph Fabre, Jerome Giustiniani, Christian Garbar, Frank Antonicelli, Yacine Merrouche, Armand Bensussan, Martine Bagot and Reem al-Dacak, Int. J. Mol. Sci. 2016.

Disruption of the CD39 immune checkpoint pathway increases the efficacy of various anticancer therapies in syngeneic mouse models

Marion Lapierre, Cécile Dejou, Carine Paturel, Henri-Alexandre Michaud, Laurent Gros, Armand Bensussan, Jean-François Eliaou, Jeremy Bastid, Nathalie Bonnefoy, AACR Annual Meeting 2016, New Orleans, April 2016.

Preclinical development of a humanized blocking anti-human CD39 antibody for anti-cancer therapy

S. Augier, I. Perrot, C. Déjou, R. Joly, S. Delahaye, H Rispaud-Blanc, C. Denis, L. Gauthier, A. Bensussan, J-F. Eliaou, Y. Morel, N Bonnefoy, J. Bastid, C. Paturel, AACR Annual Meeting 2016, New Orleans, April 2016.

See all events